Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation

Authors:

Abstract
The aim of the present study was to investigate the therapeutic efficacy of immunotherapy after microwave ablation (MWA), which was used to improve liver function, reduce the recurrence rate and enhance survival period in patients with hepatocellular carcinoma (HCC). Between February 2009 and December 2010, 14 patients received immunotherapy after MWA (immunotherapy group) and 15 patients received MWA alone with no post-ablated adjuvant therapy (control group). Immune and liver parameters, recurrence rate and survival time were recorded. The absolute lymphocyte count in the immunotherapy group exceeded that in the control group after 3 courses of immunotherapy (P0.05); however, certain cytotoxic subsets (CD3(+)/CD8(+), CD8(+)CD28(+) and CD3(+)CD16(+)CD56(+) T cells) were over-represented and negative regulatory or helper subsets (CD4(+)CD8(+), CD4(+), CD4(+)CD25(+)) were under-represented in the immunotherapy group between 1 and 12 months after immunotherapy (P0.05). In conclusion, the results of the present study indicate that immunotherapy improves the immune status and liver function of patients with HCC.

This publication has 22 references indexed in Scilit: